Adjuvant therapy for lung neuroendocrine neoplasms

Authors

Robert A. Ramirez, Vanderbilt University Medical Center
Katharine Thomas, LSUHSC New Orleans
Aasems Jacob, University of Kentucky
Karen Lin, Brookwood Baptist Health
Yvette Bren-Mattison, LSUHSC New OrleansFollow
Aman Chauhan, University of Kentucky

Document Type

Article

Publication Date

8-24-2021

Publication Title

World journal of clinical oncology

Abstract

Pulmonary neuroendocrine neoplasms (NENs) represent a minority of lung cancers and vary from slower growing pulmonary carcinoid (PC) tumors to aggressive small cell lung cancer (SCLC). While SCLC can account for up to 15% of lung cancer, PCs are uncommon and represent about 2% of lung cancers. Surgical resection is the standard of care for early-stage PCs and should also be considered in early stage large cell neuroendocrine carcinoma (LCNEC) and SCLC. Adjuvant treatment is generally accepted for aggressive LCNEC and SCLC, however, less well established for PCs. Guidelines admit a lack of trials to support a high-level recommendation for adjuvant therapy. This manuscript will discuss the role for adjuvant therapy in NENs and review the available literature.

PubMed ID

34513600

Volume

12(8)

Recommended Citation

Ramirez, Robert A.; Thomas, Katharine; Jacob, Aasems; Lin, Karen; Bren-Mattison, Yvette; and Chauhan, Aman, "Adjuvant therapy for lung neuroendocrine neoplasms" (2021). School of Medicine Faculty Publications. 1238.
https://digitalscholar.lsuhsc.edu/som_facpubs/1238
10.5306/wjco.v12.i8.664